Skip to main content
. 2021 Sep 28;7(5Part A):615–624. doi: 10.1016/j.ijwd.2021.09.009

Table 3.

Cutaneous adverse events induced by targeted therapies: synthesis table.

EGFRi c-kit inhibitors BCRABLi Angiogenesis agents FGFRi BRAFi MEKi mTORi PI3Ki HHi JAKi PARPi
Papulopustular eruption X X
Exanthema (nonspecific rash) X X X
Keratinocytic proliferation
Eruption
Benign and malignant neoplasms

X

X

X
X

X

X
Hand–foot skin reaction X X X
Hair changes (alopecia, trichomegaly, hirsutism, kinking) X X X
Nail changes
Paronychia and pyogenic granuloma
Onycholysis

X

X

X
Xerosis/fissures X X X
Oral
Mucositis
Stomatitis
Dysgeusia
Xerostomia

X

X

X

X
Hypopigmentation X X
Photosensitivity reaction X X X
Panniculitis X
Melanocytic lesion changes X

BCR–ABLi = breakpoint cluster region gene–Abelson proto-oncogene inhibitors; EGFRi = epidermal growth factor receptor inhibitors; FGFRi = fibroblast growth factor receptor inhibitors; HHi = hedgehog inhibitors; JAKi = Janus kinase inhibitos; MEKi = mitogen-activated extracellular kinase inhibitors; mTORi = mammalian target of rapamycin inhibitors; PARPi = poly-ADP ribose polymerase inhibitors; PI3Ki = phosphatidylinositol-3-kinase inhibitors